Glaxo's Acne Drug Gets U.S. Nod - Analyst Blog - NASDAQ

GlaxoSmithKline ( GSK) recently announced that its subsidiary Stiefel's Fabior (tazarotene) Foam, 0.1%, received approval from the U.S. Food and Drug Administration (FDA). Fabior Foam, 0.1% is approved as a topical treatment for acne vulgaris in ...

US FDA approves Stiefel's Fabior Foam, 0.1% to treat acne - pharmabiz.com

The US Food and Drug Administration has approved Stiefel's, a GSK company, New Drug Application for Fabior (tazarotene) Foam, 0.1 per cent. It is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age ...

Stiefel receives US FDA approval of Fabior Foam, 0.1% - Phramalive.com

RESEARCH TRIANGLE PARK, N.C., May 11, 2012 /PRNewswire/ -- Stiefel, a GSK (NYSE: GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid in a ...

FDA approves GSK topical acne treatment - SmartBrief

Want to see more news summaries? Sign up for AHIP Solutions SmartBrief AHIP Solutions SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news ...

FDA approves GSK's topical acne treatment Fabior - SmartBrief

GlaxoSmithKline received FDA approval to market Fabior, or tazarotene foam, a retinoid for those age 12 and older with acne vulgaris. The foam is contraindicated in pregnancy and might harm the fetus, the company said.